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Context. Malignant bowel obstruction (MBO) impairs the quality of life in patients 23 
with advanced cancer. Octreotide, acid-suppressing medications such as H2-receptor 24 
antagonists (H2 blockers) and proton pump inhibitors (PPIs), and corticosteroids are 25 
often used in combination for symptom control. 26 
Objectives. We evaluated the practice patterns of medications for patients hospitalized 27 
with MBO using a large claims database in Japan. Additionally, we explored the 28 
association of adding H2-blockers/PPIs or corticosteroids to octreotide on treatment 29 
outcomes. 30 
Methods. We analyzed data from a nationwide medical claims database from April 31 
2010 to March 2015 containing 975,000 patients. We included all adult inpatients with 32 
cancer who used octreotide 300 µg/day or more and summarized each patient’s 33 
medication use. We also assessed whether concomitant use of H2-blockers/PPIs or 34 
corticosteroids was associated with the number of days of nasogastric tube (NGT) 35 
insertion; logistic regression was used to adjust the patients’ baseline factors. 36 
Results. We included 3,090 patients; octreotide alone was used in 1,649 (53%) cases. A 37 
combination of octreotide and H2-blockers or PPIs was used in 419 and 337 cases (14% 38 
and 11%), respectively; a combination of octreotide and corticosteroids was used in 374 39 
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cases (12%). Of the 1,595 patients who underwent NGT insertion, those using 40 
corticosteroids with octreotide had a higher odds ratio (OR) of NGT removal within 4 41 
days of insertion (adjusted OR=1.16; 95% confidence interval = 1.08–1.23). 42 
Conclusion. Octreotide alone was used in the majority of patients, and the concomitant 43 
use of corticosteroids was more likely to be associated with early NGT removal. 44 
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Malignant bowel obstruction (MBO) is a common complication in patients with 59 
advanced cancer with an incidence of 3%–15% (1-6). Symptoms include abdominal 60 
pain, colic, nausea, vomiting, and abdominal swelling; these symptoms markedly impair 61 
the patients’ quality of life (1-6). While surgical treatment can be a treatment option for 62 
some patients with MBO, a pharmacological approach is principally used in palliative 63 
care settings (1-6). Key medications include octreotide, acid-suppressing medications 64 
such as H2-receptor antagonists (H2 blockers) and proton pump inhibitors (PPIs), and 65 
corticosteroids (1-6). Existing empirical studies suggest octreotide (7-11), acid-66 
suppressing medications such as H2 blockers and PPIs (12, 13), and corticosteroids (14-67 
16) are effective in alleviating the symptoms of MBO, but a recent randomized 68 
controlled trial revealed that octreotide administration demonstrated no additional 69 
benefit for patients who received H2 blockers/PPIs, corticosteroids, and 70 
butylscopolamine as part of their standard treatment (17). In clinical settings, these 71 
medications are commonly used in combination, and it is important to explore the 72 
current practice of drug combination in patients with MBO and the association between 73 
treatment outcomes and drug combinations (6). To date, however, no nationwide studies 74 
have examined how these drugs are used in actual clinical settings. Examining the 75 
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treatment effects of drugs in actual clinical settings, not only in clinical trials, is 76 
valuable for the interpretation of research findings (18,19). 77 
Thus, the primary aim of this study was to describe the practice patterns of 78 
medications for patients hospitalized with MBO using a nationwide claims database. The 79 
secondary aim was to explore the association of adding H2-blockers/PPIs or 80 
corticosteroids to octreotide on treatment outcomes. 81 
 82 
METHODS 83 
This study was a database analysis using nationwide claims data from about 10 million 84 
patients in Japan. The study was approved by the ethics committee of Kyoto University 85 
and the need for informed consent was waived because of the use of anonymous data only.  86 
 87 
Data Sources 88 
This study was conducted using the Japanese Medical Data Vision database, a 89 
commercial, electronic, record-based healthcare database. This database contains 90 
patient-level information on demographic characteristics, diagnoses coded according to 91 
the International Classification of Diseases, 10th revision (ICD-10), clinical data, and 92 
prescription information such as dose, quantity, and number of days of supply. The 93 
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database contains data on inpatient and outpatient medical care from a panel of 192 94 
hospitals distributed in different regions throughout Japan and includes 975,000 95 
patients. The age and sex distribution of the patients in the database is similar to that of 96 
the national demographic profile of individuals seeking healthcare (20). Patient 97 
identities were encrypted for protection of privacy.  98 
 99 
Case Definition 100 
All patients recorded in the database from April 2010 to March 2015 were screened. No 101 
specific ICD-10 codes for MBO existed, and our primary aim was to investigate how 102 
octreotide was used in the palliative care of cancer patients; thus, we decided to include 103 
adult inpatients with a diagnosis of intraabdominal cancers, i.e., cancers of the esophagus, 104 
stomach, small and large intestine, liver, pancreas, bile duct system, or ovary, who used 105 
octreotide 300 µg/day or more. We excluded patients who received once-a-month 106 
octreotide because it was reasonably assumed that the monthly type somatostatin analog 107 
was used for endocrine disease. We also excluded patients who underwent surgical 108 
management including stenting or percutaneous endoscopic gastrostomy (PEG). We also 109 
excluded patients who had other primary tumor sites and those who did not have a 110 
diagnosis recorded. 111 
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Outcome Measures 112 
The main outcome measure was the prescription patterns of drugs used concomitantly 113 
with octreotide, i.e., the number of patients who received H2 blockers/PPIs and 114 
corticosteroids. We also recorded the use of butylscopolamine. We defined the first 115 
octreotide prescription day as the index day for each patient and identified any 116 
concomitant drugs that were used on the index day. To extract information on concomitant 117 
drugs, we limited the search to drugs using the Anatomical Therapeutic Chemical 118 
Classification System (Supplemental Table 1), a drug classification system defined by the 119 
World Health Organization. If such medications were administered on the index day, we 120 
judged that there was concomitant use regardless of the period. For corticosteroids, 121 
generic names and prescription period were also recorded. We calculated the daily 122 
hydration volume of the index day and classified it as less than 1000 ml/day or 1000 123 
mL/day or more. 124 
As a secondary endpoint, for the subgroup of patients who had undergone 125 
nasogastric tube (NGT) insertion on the index day, we calculated the total number of days 126 
of NGT insertion. Although we believe that patient-reported outcomes such as intensity 127 
of nausea or frequency of vomiting are important, such data was unavailable in the claims 128 
database. Therefore, we decided to use claims data of NGT as a surrogacy outcome. The 129 
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total number of days of NGT insertion was calculated from the first day when the patient 130 
received octreotide (index day) to the day before the end of the NGT insertion or the day 131 
the patient died or was discharged. Claims data recorded NGT insertion once daily as 132 
long as it remained in place. In addition, information about disease-specific variables, 133 
including age, sex, primary sites of cancer, clinical department, and length of hospital 134 
stay was obtained. 135 
 136 
Statistical analyses 137 
Patterns and frequency of drug administration are presented as numbers with percentages. 138 
For the secondary endpoint, we analyzed the patients who had undergone NGT insertion 139 
on the index day. Initially, we compared the NGT period (days) among the groups of 140 
octreotide alone, octreotide plus H2-blockers, octreotide plus PPIs, octreotide plus 141 
corticosteroids, and octreotide plus H2-blockers/PPIs plus corticosteroids. We used the 142 
Wilcoxon rank sum test. Second, we calculated the adjusted odds ratio (OR) for the days 143 
of NGT removal using logistic regression analysis. The OR was calculated using the 144 
patients who received octreotide alone as a reference and was adjusted by sex, age, 145 
hydration volume, use of butylscopolamine, and type of cancer. Additional analysis was 146 
performed to confirm the robustness of the results: 1) we divided the period of NGT 147 
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insertion into 3 groups as follows: NGT removed within 4 days, within 7 days, and after 148 
more than 14 days; 2) we performed subgroup analyses on patients with different 149 
hydration volumes (<1000 mL/day vs. 1000 mL/day or more, 1000 mL/day or less vs. 150 
more than 1000 mL/day, and <1500 mL/day vs. 1500 mL/day or more); and 3) we 151 
performed subgroup analyses on patients with and without butylscopolamine use. 152 
Because of the exploratory nature of this study, a p-value <0.05 was considered 153 
statistically significant. Analyses were performed using SAS, version 9.4 (SAS Institute, 154 
Cary, NC).  155 
 156 
RESULTS 157 
Baseline Characteristics 158 
Of the 6,495 patients who used octreotide, a total of 3,090 patients met our study 159 
eligibility criteria (Fig. 1). Table 1 shows the baseline characteristics of the patients. The 160 
mean age of the patients was 67 years, and stomach cancer was the most prevalent type 161 
of cancer. A hydration volume of 1000 ml/day or more was observed in 1,720 (56%) cases. 162 
The median of hydration volume was 1000 ml/day (interquartile range [IQR]: 500-1365). 163 
A total of 1,595 (52%) patients who underwent NGT insertion were identified. Among 164 
them, 1,016 patients (76%) survived for the entire study period, and the median number 165 
of days that each patient survived was 11 days. Butylscopolamine was used in 4.4% of 166 
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the cases. 167 
 168 
 169 
Patterns and frequency of drug administration 170 
Octreotide was used without H2-blockers/PPIs or corticosteroids in 1,649 (53%) cases 171 
(Table 2). A combination of octreotide and H2-blockers and PPIs was observed in 419 and 172 
337 cases (14% and 11%), respectively; and a combination of octreotide and 173 
corticosteroids was observed in 374 (12%) cases. Types of corticosteroids were: 174 
dexamethasone in 206 cases (55%), betamethasone in 116 cases (31%), prednisolone in 175 
11 cases (5.1%), and others in 22 (5.9%) cases. 176 
 177 
Association of drug combinations on NGT removal 178 
The 1,595 patients who had undergone NGT insertion were included in this subgroup 179 
analysis (52%). In univariate analysis, patients treated with corticosteroids had a 180 
significantly shorter median period of NGT insertion than those who did not use 181 
corticosteroids (9 vs. 13 days, P<0.001; Table 3). After adjusting for sex, age, hydration 182 
volume, use of butylscopolamine, and type of cancer, the results were unchanged; the 183 
combined use of corticosteroids with octreotide was associated with a shorter period of 184 
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NGT insertion (Table 4). Patients using corticosteroids with octreotide had a higher OR 185 
of removal within 4 days (adjusted OR=1.16; 95% CI=1.08–1.23) and 7 days (adjusted 186 
OR=1.14; 95% CI=1.07–1.21) and a lower OR of NGT retention after 14 days (adjusted 187 
OR=0.86; 95% CI=0.81–0.91).  188 
Subgroup analyses on patients with a hydration volume of <1000 mL/day and 189 
1000 mL/day or more revealed the essentially same results (Supplemental Table 2). 190 
Sensitivity analyses using different cut-off points (i.e., ≤1000 mL vs. 1000 mL<, <1500 191 
mL vs. ≤1500 mL) and subgroup analyses on the patients with or without the use of 192 
butylscopolamine achieved the same results (data not shown).  193 
 194 
DISCUSSION 195 
MBO is relatively common in palliative care settings, but to date, few studies have 196 
identified the drug combination profiles administered to patients with MBO in actual 197 
clinical settings (21). In this study, we revealed that use of octreotide alone was the most 198 
common (53%), followed by octreotide in combination with H2 blockers/PPIs (14/11%), 199 
and corticosteroids (12%). This finding suggests that, although a combination of H2 200 
blockers/PPIs and corticosteroids is recommended for palliative treatment of MBO (1-6), 201 
octreotide is currently more likely to be used without these medications. Further studies 202 
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from other countries will be valuable to obtain further insights into current practices in 203 
the management of MBO. 204 
We defined the length of NGT insertion as a surrogate marker for medical 205 
treatment, revealing that the length of insertion was significantly shorter in the group 206 
using corticosteroids in combination with octreotide. Patients who had been administered 207 
corticosteroids were more likely to undergo early NGT removal. This may be 208 
pharmacologically plausible because the anti-inflammatory effect leads to the reopening 209 
of the bowel occlusion owing to reduction of the edema caused by the tumor (14). A trend 210 
toward an early resolution of obstructions with the combined use of octreotide and 211 
corticosteroids supports the conclusion of the existing meta-analysis of clinical trials (14). 212 
In patients receiving octreotide, the addition of corticosteroids may be more effective in 213 
palliating symptoms of MBO. Some clinicians have concerns that the use of 214 
corticosteroids is associated with serious side effects such as infection, hyperglycemia, 215 
and psychiatric complications (14). However, the overall frequency of such side effects 216 
was estimated to be low in previous studies (22,24). As there is still uncertainty regarding 217 
both the benefits and potentially harmful effects of corticosteroids for MBO, the benefit 218 
of corticosteroids for MBO should be further evaluated in comprehensive outcomes in 219 
both clinical trials and real-world studies. We found that 48% of our patients were 220 
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managed without NGT. Thus, the pharmacological management of those patients is 221 
relatively important. 222 
Of note, a combination of acid-reducing agents such as H2 blockers/PPIs and 223 
octreotide resulted in prolonged NGT administration as compared with octreotide alone. 224 
The potential interpretation is that patients with obstruction of the upper intestines were 225 
more likely to receive acid-reducing agents and were less likely to experience the benefits 226 
of octreotide (24). Further studies are necessary to confirm why the use of acid-reducing 227 
agents is associated with poor outcomes in patients with MBO.  228 
This study has several strengths. First, the study was designed based on real-229 
world clinical settings using a nation-wide database. Second, NGT removal was used as 230 
a surrogacy index of symptoms such as nausea and vomiting. This outcome is objective. 231 
Nonetheless, this study had several limitations. First, MBO occurs more frequently in 232 
patients with advanced cancer (5), but this database obtained no data about the clinical 233 
stage of cancer. Second, the side effects of corticosteroids were not investigated in this 234 
study. Although corticosteroids were associated with a shorter duration of NGT insertion, 235 
it is unclear whether this benefit outweighed the adverse effects of corticosteroids; thus, 236 
further studies addressing these issues are warranted. Third, the definition of concomitant 237 
use was based on only the index day, and differences in the timing of administration and 238 
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MBO severity was not investigated. Finally, this database contained no data about the 239 
reasons for NGT insertion and removal. Although we believe it is reasonable to regard 240 
NGT removal as an index of improvement because surgical patients were excluded, our 241 
results should be interpreted with caution because of the nature of this study.  242 
In summary, we found that octreotide alone was used in the majority of patients, 243 
and use of corticosteroids was more likely to be associated with early NGT removal. 244 
Further clinical trials and observational studies are needed to clarify the role of drug 245 
combinations in managing MBO. 246 
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Table 1. Baseline characteristics (N=3,090 patients) 
SD: standard deviation; IQR: interquartile range    
  
Age, mean (SD)   67 (11.8) 
Sex, N (%) Male 1,758 (57) 
 Female 1,332 (43) 
Primary sites of cancer, N (%) Stomach 1042 (33) 
 Large intestine 813 (26.3) 
 Pancreas 579 (18.7) 
 Bile duct system 285 (9.2) 
 Ovary 208 (6.7) 
 Esophagus  94 (3.0) 
 Liver 64 (2.1) 
 Small intestine 5 (0.2) 
Clinical department, N (%) Surgery 1,711 (55) 
 Internal medicine 998 (32) 
 Gynecology 161 (5) 
 Palliative medicine 32 (1) 
 Others 188 (6) 
Length of stay, median (IQR)  30 (15–54) 
Use of butylscopolamine (%)  135 (4.4) 
Hydration volume, N (%) <1000 ml/day 1,370 (44) 
 1000 ml/day or more 1,720 (56) 
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Table 2. Drug prescription patterns (N=3,090 patients) 
Combinations N % 95% CI 
Octreotide 1649 53 52 – 55 
Octreotide + H2 blockers 419 14 12 – 15 
Octreotide + Corticosteroid 374 12 11 – 13 
Octreotide + PPIs 337 11 10 – 12 
Octreotide + Corticosteroid + H2 blockers 141 4.6 4.0 – 5.0 
Octreotide + Corticosteroid + PPIs 95 3.1 2.0 – 4.0 
Octreotide + PPIs + H2 blockers 65 2.1 2.0 – 3.0 
Octreotide + PPIs + H2 blockers + Corticosteroid 10 0.3 0.1 – 0.5 





Table 3. Number of patients with concomitant drugs and days with NGT (N=1,595) 
  Period of NGTa (IQRb) P valuec 
H2 blockers   
use (n=390) 13 (4–28) 0.49 
no use (n=1205) 12 (5–27)  
PPIs   
use (n=328) 14 (7–27.8) 0.04 
no use (n=1267) 12 (4–27)  
Corticosteroid   
use (n=211) 9 (4–19) <0.001 
no use (n=1384) 13 (5–29)  
H2 blockers/PPIs+ Corticosteroid   
use (n=101) 9 (4–19) 0.01 
no use (1494)   12 (5–28)   
NGT: nasogastric tube; H2 blockers: Histamine H2 – receptor antagonist; PPIs: proton pump inhibitors; ain 




Table 4. Association of concomitant medications (N=1,595) 
 
  NGT removal within 4 days NGT removal within 7 days NGT in place for more than 14 days 
 Odds ratioa 95% CI 
P 
value 
Odds ratioa 95% CI 
P 
value 
Odds ratioa 95% CI P value 
Octreotide alone (n=666) 1.0(reference)   1.0(reference)   1.0(reference)   
Octreotide + H2 blocker 
(n=390)  0.89 0.83 0.95 0.001 0.89 0.83 0.94 0.0002 1.05 0.99 1.11 0.11 
Octreotide + PPI (n=328) 0.84 0.78 0.90 <.0001 0.83 0.78 0.89 <.0001 1.07 1.01 1.14 0.02 
Octreotide + 
Corticosteroid (n=211) 
1.16 1.08 1.23 <.0001 1.14 1.07 1.21 <.0001 0.86 0.81 0.91 <.0001 
NGT: nasogastric tube; OR: odds ratio; 95% CI: 95% confidence interval; H2 blockers: Histamine H2 – receptor antagonist; PPIs: proton pump inhibitors  
aMultivariate analyses adjusted for sex, age, hydration volume, use of butylscopolamine and type of cancer
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Figure 1. Flow diagram of the selection of study individuals 
Patients who were administered octreotide in 




      
Diagnosed with intra-abdominal cancers *  




      
Older than 19 years  N=4,962 
 
  
      
Once-a-month 
octreotide 
      N=190 
Use of octreotide 300 µg/day or more  N=4,249 
 
  
      
Received stenting and 
surgical treatment 
      N=37 
Diagnosed with intraabdominal cancers * on 




      
Other primary tumor 
sites or unreported 
      N=1,122 
Diagnosed with intraabdominal cancers * on 
the index day 
 N=3,090  







Supplemental Table 1. Concomitant Drugs and Anatomical Therapeutic Chemical 
Classification System (ATC code) 
ATC name ATC code Representative drug 
Antigrowth hormone H01C2 Octreotide 
Butylscopolamine A03A0 Butyl scopolamine bromide 




Proton pump inhibitor A02B2 Omeprazole 
Rabeprazole 
Lansoprazole 










Supplemental Table 2. Association of concomitant medications by hydration volume 
 <1000 ml (N=683)            
  NGT removal within 4 days NGT removal within 7 days NGT in place for more than 14 days 
 Odds ratio 95% CI 
P 
value 
Odds ratio 95% CI 
P 
value 
Odds ratio 95% CI P value 
Octreotide alone 
(n=212) 
1.0(reference)   1.0(reference)   1.0(reference)   
Octreotide + H2 
blocker (n=214)  0.89 0.80 0.98 0.018 0.90 0.82 0.99 0.03 1.06 0.97 1.15 0.18 
Octreotide + PPI 
(n=196) 
0.94 0.84 1.04 0.24 0.93 0.84 1.03 0.18 1.05 0.96 1.15 0.28 
Octreotide + 
Corticosteroid (n=61) 
1.14 1.04 1.26 0.005 1.11 1.01 1.21 0.03 0.90 0.83 0.97 0.01 
NGT: nasogastric tube; OR: odds ratio; 95% CI: 95% confidence interval; H2 blockers: Histamine H2 – receptor antagonist; PPIs: proton pump inhibitors  









 ≥1000 ml (N=912)         
  NGT removal within 4 days NGT removal within 7 days NGT in place for more than 14 days 
 Odds ratio 95% CI P value Odds ratio 95% CI P value Odds ratio 95% CI P value 
Octreotide alone 
(n=454) 
1.0(reference)   1.0(reference)   1.0(reference)   
Octreotide + H2 
blocker (n=176)  0.91 0.83 0.99 0.035 0.89 0.81 0.97 0.0060 1.04 0.96 1.13 0.35 
Octreotide + PPI 
(n=132) 
0.80 0.73 0.87 <0.0001 0.79 0.72 0.86 <0.0001 1.09 1.00 1.18 0.06 
Octreotide + 
Corticosteroid (n=150) 
1.17 1.07 1.27 <0.0001 1.18 1.08 1.28 <0.0001 0.83 0.77 0.90 <0.0001 
NGT: nasogastric tube; OR: odds ratio; 95% CI: 95% confidence interval; H2 blockers: Histamine H2 – receptor antagonist; PPIs: proton pump inhibitors  
aMultivariate analyses adjusted for sex, age, use of butylscopolamine and type of cancer 
 
 
